Piper Sandler reiterates Overweight rating on GeneDx stock, citing multiyear growth potential

Published 04/08/2025, 16:12
Piper Sandler reiterates Overweight rating on GeneDx stock, citing multiyear growth potential

Investing.com - Piper Sandler maintained its Overweight rating and $120.00 price target on GeneDx (NASDAQ:WGS), now valued at nearly $3 billion, following the company’s recent earnings report. According to InvestingPro data, the stock maintains a "GOOD" financial health score, with analysts’ targets ranging from $95 to $125.

The research firm raised its revenue projections for GeneDx after the company beat expectations and increased its own guidance last week. The company has demonstrated strong momentum with 48.7% revenue growth in the last twelve months.

Piper Sandler identified potential upside to average selling prices for this year, along with possible revenue and operating margin improvements in subsequent years.

The firm described GeneDx as a "compelling multi-year growth story" in its research note, highlighting the company’s strategic positioning in the genetic testing market.

Piper Sandler believes GeneDx is well-positioned to expand its services beyond geneticists to neonatal intensive care units (NICU), pediatricians, and eventually the broader newborn screening market.

In other recent news, GeneDx Holdings Corp reported impressive financial results for the second quarter of 2025. The company significantly exceeded earnings and revenue forecasts, with earnings per share reaching $0.50, far surpassing the anticipated $0.12. Revenue for the quarter was reported at $102.7 million, which is a 20.19% increase over the forecasted $85.45 million. Following these results, BTIG raised its price target for GeneDx to $125 from $100, while maintaining a Buy rating. BTIG highlighted the company’s strong performance, noting a "strong bounce-back" in Q2 that exceeded top-line expectations by more than $17 million and surpassed bottom-line forecasts by $15 million. These developments mark a significant achievement for GeneDx in the recent quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.